Jaguar Health Inc (NASDAQ:JAGX) was the recipient of a significant decrease in short interest during the month of March. As of March 29th, there was short interest totalling 309,546 shares, a decrease of 56.2% from the March 15th total of 707,275 shares. Based on an average daily trading volume, of 26,815,240 shares, the short-interest ratio is currently 0.0 days. Currently, 0.8% of the shares of the company are sold short.

Separately, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research report on Friday, April 5th.

Shares of NASDAQ JAGX opened at $0.22 on Tuesday. Jaguar Health has a 52 week low of $0.12 and a 52 week high of $3.20. The company has a quick ratio of 0.31, a current ratio of 0.46 and a debt-to-equity ratio of 1.03.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

See Also: Quiet Period Expirations

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.